Showing results (161-170 of 225) with videos related to

Sort By:
Pageof 23
Clinical Colorectal Cancer|December 17, 2016
Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver MetastasesFilippo Pietrantonio, Maria Di Bartolomeo, Christian Cotsoglou, et al.
Nature Communications|August 30, 2020
Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinomaGianluca Ianiro, Ernesto Rossi, Andrew M Thomas, et al.
BJU International|February 28, 2012
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian surveyCristina Masini, Roberto Sabbatini, Camillo Porta, et al.
Life (Basel, Switzerland)|June 26, 2026
Correction: Schubert et al. Minimally Invasive Ablation Strategies for Renal Cell Carcinoma Patients Ineligible for Surgery. Life 2026, 16, 73Or Schubert, Maria Chiara Sighinolfi, Filippo Gavi, et al.
World Journal of Clinical Oncology|December 15, 2021
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case seriesSebastiano Buti, Melissa Bersanelli, Francesco Massari, et al.
Tumori|May 4, 2026
International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinomaAlessandro Rametta, Sebastiano Buti, Marco Stellato, et al.
The New England Journal of Medicine|October 1, 2019
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate CancerRonald de Wit, Johann de Bono, Cora N Sternberg, et al.
European Urology Oncology|July 11, 2025
Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysisFabiano Flauto, Giuseppe Neola, Carmine Caso, et al.
Cancer Immunology, Immunotherapy : CII|February 25, 2026
Pattern of disease recurrence and outcomes after progression of high-risk renal cell carcinoma (RCC) patients treated with adjuvant immunotherapyChiara Ciccarese, Denis Occhipinti, Daniela Arduini, et al.
Urologic Oncology|February 11, 2025
SIRI as a biomarker for bladder neoplasm: Utilizing decision curve analysis to evaluate clinical net benefitPierluigi Russo, Nazario Foschi, Giuseppe Palermo, et al.
Pageof 23